Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically.
Deucrictibant is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist. Pharvaris is developing two distinct formulations of deucrictibant to address unmet needs in both the on-demand (via immediate-release capsule) and prophylactic (via extended-release tablet) treatment paradigms.
With positive data in both Phase 2 on-demand and Phase 2 prophylaxis studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months.
